337 related articles for article (PubMed ID: 24024144)
1. Nitric oxide-releasing prodrug triggers cancer cell death through deregulation of cellular redox balance.
Maciag AE; Holland RJ; Robert Cheng YS; Rodriguez LG; Saavedra JE; Anderson LM; Keefer LK
Redox Biol; 2013; 1(1):115-24. PubMed ID: 24024144
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs.
Chakrapani H; Kalathur RC; Maciag AE; Citro ML; Ji X; Keefer LK; Saavedra JE
Bioorg Med Chem; 2008 Nov; 16(22):9764-71. PubMed ID: 18930407
[TBL] [Abstract][Full Text] [Related]
3. The nitric oxide prodrug JS-K is effective against non-small-cell lung cancer cells in vitro and in vivo: involvement of reactive oxygen species.
Maciag AE; Chakrapani H; Saavedra JE; Morris NL; Holland RJ; Kosak KM; Shami PJ; Anderson LM; Keefer LK
J Pharmacol Exp Ther; 2011 Feb; 336(2):313-20. PubMed ID: 20962031
[TBL] [Abstract][Full Text] [Related]
4. A reactive oxygen species activation mechanism contributes to JS-K-induced apoptosis in human bladder cancer cells.
Qiu M; Chen L; Tan G; Ke L; Zhang S; Chen H; Liu J
Sci Rep; 2015 Oct; 5():15104. PubMed ID: 26458509
[TBL] [Abstract][Full Text] [Related]
5. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity.
Shami PJ; Saavedra JE; Wang LY; Bonifant CL; Diwan BA; Singh SV; Gu Y; Fox SD; Buzard GS; Citro ML; Waterhouse DJ; Davies KM; Ji X; Keefer LK
Mol Cancer Ther; 2003 Apr; 2(4):409-17. PubMed ID: 12700285
[TBL] [Abstract][Full Text] [Related]
6. Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs.
Maciag AE; Nandurdikar RS; Hong SY; Chakrapani H; Diwan B; Morris NL; Shami PJ; Shiao YH; Anderson LM; Keefer LK; Saavedra JE
J Med Chem; 2011 Nov; 54(22):7751-8. PubMed ID: 22003962
[TBL] [Abstract][Full Text] [Related]
7. Cellular distribution studies of the nitric oxide-generating antineoplastic prodrug O(2) -(2,4-dinitrophenyl)1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate formulated in Pluronic P123 micelles.
Kaur I; Terrazas M; Kosak KM; Kern SE; Boucher KM; Shami PJ
J Pharm Pharmacol; 2013 Sep; 65(9):1329-36. PubMed ID: 23927471
[TBL] [Abstract][Full Text] [Related]
8. Hybrid molecule from O2-(2,4-dinitrophenyl)diazeniumdiolate and oleanolic acid: a glutathione S-transferase π-activated nitric oxide prodrug with selective anti-human hepatocellular carcinoma activity and improved stability.
Fu J; Liu L; Huang Z; Lai Y; Ji H; Peng S; Tian J; Zhang Y
J Med Chem; 2013 Jun; 56(11):4641-55. PubMed ID: 23617697
[TBL] [Abstract][Full Text] [Related]
9. TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells.
Simeone AM; McMurtry V; Nieves-Alicea R; Saavedra JE; Keefer LK; Johnson MM; Tari AM
Breast Cancer Res; 2008; 10(3):R44. PubMed ID: 18474097
[TBL] [Abstract][Full Text] [Related]
10. NG as a novel nitric oxide donor induces apoptosis by increasing reactive oxygen species and inhibiting mitochondrial function in MGC803 cells.
Liu L; Li T; Tan J; Fu J; Guo Q; Ji H; Zhang Y
Int Immunopharmacol; 2014 Nov; 23(1):27-36. PubMed ID: 25135879
[TBL] [Abstract][Full Text] [Related]
11. JS-K as a nitric oxide donor induces apoptosis via the ROS/Ca
Huang Z; Liu L; Chen J; Cao M; Wang J
Biomed Pharmacother; 2018 Nov; 107():1385-1392. PubMed ID: 30257354
[TBL] [Abstract][Full Text] [Related]
12. Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation.
Liu J; Li C; Qu W; Leslie E; Bonifant CL; Buzard GS; Saavedra JE; Keefer LK; Waalkes MP
Mol Cancer Ther; 2004 Jun; 3(6):709-14. PubMed ID: 15210857
[TBL] [Abstract][Full Text] [Related]
13. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells.
Laschak M; Spindler KD; Schrader AJ; Hessenauer A; Streicher W; Schrader M; Cronauer MV
BMC Cancer; 2012 Mar; 12():130. PubMed ID: 22462810
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivo.
Shami PJ; Saavedra JE; Bonifant CL; Chu J; Udupi V; Malaviya S; Carr BI; Kar S; Wang M; Jia L; Ji X; Keefer LK
J Med Chem; 2006 Jul; 49(14):4356-66. PubMed ID: 16821795
[TBL] [Abstract][Full Text] [Related]
15. JS-K, a nitric oxide prodrug, induces cytochrome c release and caspase activation in HL-60 myeloid leukemia cells.
Udupi V; Yu M; Malaviya S; Saavedra JE; Shami PJ
Leuk Res; 2006 Oct; 30(10):1279-83. PubMed ID: 16439016
[TBL] [Abstract][Full Text] [Related]
16. JS-K, a nitric oxide donor, induces autophagy as a complementary mechanism inhibiting ovarian cancer.
Liu B; Huang X; Li Y; Liao W; Li M; Liu Y; He R; Feng D; Zhu R; Kurihara H
BMC Cancer; 2019 Jul; 19(1):645. PubMed ID: 31262254
[TBL] [Abstract][Full Text] [Related]
17. JS-K, a novel non-ionic diazeniumdiolate derivative, inhibits Hep 3B hepatoma cell growth and induces c-Jun phosphorylation via multiple MAP kinase pathways.
Ren Z; Kar S; Wang Z; Wang M; Saavedra JE; Carr BI
J Cell Physiol; 2003 Dec; 197(3):426-34. PubMed ID: 14566972
[TBL] [Abstract][Full Text] [Related]
18. JS-K, a glutathione S-transferase-activated nitric oxide donor with antineoplastic activity in malignant gliomas.
Weyerbrock A; Osterberg N; Psarras N; Baumer B; Kogias E; Werres A; Bette S; Saavedra JE; Keefer LK; Papazoglou A
Neurosurgery; 2012 Feb; 70(2):497-510; discussion 510. PubMed ID: 21849924
[TBL] [Abstract][Full Text] [Related]
19. Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI.
Weidensteiner C; Reichardt W; Shami PJ; Saavedra JE; Keefer LK; Baumer B; Werres A; Jasinski R; Osterberg N; Weyerbrock A
Nitric Oxide; 2013 Apr; 30():17-25. PubMed ID: 23370169
[TBL] [Abstract][Full Text] [Related]
20. Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53.
Kitagaki J; Yang Y; Saavedra JE; Colburn NH; Keefer LK; Perantoni AO
Oncogene; 2009 Jan; 28(4):619-24. PubMed ID: 18978812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]